Psoriatic arthritis (PsA) presents with diverse manifestations, including peripheral arthritis, enthesitis, tenosynovitis, dactylitis, axial involvement, and skin and nail psoriasis. The condition is often complicated by comorbidities such as cardiovascular disease, diabetes mellitus, metabolic syndrome, gout, anxiety, and depression. Management approaches encompass both non-pharmacological and pharmacological interventions. Non-pharmacological strategies include patient education, lifestyle modifications, physiotherapy, and occupational therapy. Pharmacological treatments are tailored to the patient’s clinical profile and may involve non-steroidal anti-inflammatory drugs (NSAIDs) for symptomatic relief; conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate, leflunomide, and sulfasalazine; and biologic and targeted synthetic DMARDs, including tumor necrosis factor-alpha (TNFα) inhibitors, phosphodiesterase 4 (PDE4) antagonists, and more. There is a need for biomarkers to predict therapeutic responses, aiming to facilitate a more personalized treatment approach for PsA patients.

Reference: Kharouf F, Gladman DD. Advances in the management of psoriatic arthritis in adults. BMJ. 2024;387:e081860. doi:10.1136/bmj-2024-081860